Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30828396 | 1.00 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL21594682 | 0.82 | HTR7 (0.43) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL31579202 | 0.82 | HTR7 (0.43) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL29835540 | 0.82 | NCF1 (0.43) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL906769 | 0.82 | NCF1 (0.43) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL19752022 | 0.78 | HTR7 (0.41) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL18884378 | 0.76 | NOS3 (0.48) | MEN1KMT2AGAAGRM5 | |
| SCHEMBL24102171 | 0.75 | TAAR1 (0.41) | HTR7HTR2AALOX5 | |
| SCHEMBL6632726 | 0.75 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2ACLK1 | |
| SCHEMBL1110998 | 0.75 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2ACLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-119954801-A | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-114867727-B | TAU protein targeting compounds and related methods of use | 阿尔维纳斯运营股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2025-01-21 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-112313230-B | Novel compounds for the treatment, alleviation or prevention of conditions associated with Tau aggregate | AC免疫有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003012-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011003021-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011003021-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202840-B2 | Compounds for the treatment or alleviation of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HTR7 3433/4885HTR1A 2874/4885DRD2 3588/4885 |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | HTR7 3750/4885HTR1A 3714/4885DRD2 4415/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | HTR7 3720/4885HTR1A 3583/4885DRD2 4284/4885 |
| US-20110003739-A1 | AZINONE-SUBSTITUTED AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | HTR7 80/4885HTR1A 10/4885DRD2 474/4885 |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | HTR7 85/4885HTR1A 11/4885DRD2 317/4885 |
| US-20110003737-A1 | AZABICYCLOALKANE-INDOLE AND AZABICYCLOALKANE-PYRROLO-PYRIDINE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | HTR7 160/4885HTR1A 24/4885DRD2 559/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | HTR7 3750/4885HTR1A 3714/4885DRD2 4415/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | HTR7 2255/4885HTR1A 2962/4885DRD2 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.